Get notified when VANI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVivani pivots to semaglutide implant NPM-139 after first-in-human trial success
Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~2 min read
Key Changes
-
high
Company shifted from dual lead programs to single focus on NPM-139 semaglutide implant after LIBERATE-1 trial showed positive safety/tolerability and preclinical data demonstrated 30% weight loss sustained for one year; Phase 1 expected mid-2026.
Business: Lead Program Prioritization verify on EDGAR → -
high
Net loss widened to $26.6M from $23.5M as R&D spending increased 15% to $18.1M; company raised $23.3M through multiple equity offerings and extended cash runway to mid-2027.
MD&A: Financial Results verify on EDGAR → -
high
Oppenheimer filed breach-of-contract lawsuit seeking $1.6M+ in damages related to failed Pixium merger; court allowed claim to proceed to discovery after dismissing other counts.
Legal Proceedings verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.
Partner
Trade VANI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify